Galectin Therapeutics Inc.

NASDAQ:GALT

1.15 (USD) • At close January 14, 2025
Bedrijfsnaam Galectin Therapeutics Inc.
Symbool GALT
Munteenheid USD
Prijs 1.15
Beurswaarde 71,654,315
Dividendpercentage 0%
52-weken bereik 0.73 - 4.27
Industrie Biotechnology
Sector Healthcare
CEO Mr. Joel Lewis
Website https://galectintherapeutics.com

An error occurred while fetching data.

Over Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated

Vergelijkbare Aandelen

Eyenovia, Inc. logo

Eyenovia, Inc.

EYEN

0.086 USD

Centogene N.V. logo

Centogene N.V.

CNTG

0.325 USD

Augmedix, Inc. logo

Augmedix, Inc.

AUGX

2.345 USD

Viracta Therapeutics, Inc. logo

Viracta Therapeutics, Inc.

VIRX

0.17 USD

Journey Medical Corporation logo

Journey Medical Corporation

DERM

3.73 USD

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

BCTX

0.39 USD

Minerva Surgical, Inc. logo

Minerva Surgical, Inc.

UTRS

0 USD

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

0.342 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)